2. Academic Validation
  3. Anagrelide: A Clinically Effective cAMP Phosphodiesterase 3A Inhibitor with Molecular Glue Properties

Anagrelide: A Clinically Effective cAMP Phosphodiesterase 3A Inhibitor with Molecular Glue Properties

  • ACS Med Chem Lett. 2023 Mar 28;14(4):350-361. doi: 10.1021/acsmedchemlett.3c00092.
Nicholas A Meanwell 1
Affiliations

Affiliation

  • 1 The Baruch S. Blumberg Institute, 3805 Old Easton Road, Doylestown, Pennsylvania 18902, United States.
PMID: 37077378 DOI: 10.1021/acsmedchemlett.3c00092
Abstract

The mode of action by which the orphan drug anagrelide (1), a potent cAMP phosphodiesterase 3A inhibitor, reduces blood platelet count in humans is not well understood. Recent studies indicate that 1 stabilizes a complex between PDE3A and Schlafen 12, protecting it from degradation while activating its RNase activity.

Figures